Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biotest AG
  6. Summary
    BIO   DE0005227201

BIOTEST AG

(BIO)
  Report
Delayed Xetra  -  05:25 2022-06-28 am EDT
42.10 EUR   -0.71%
06/10BIOTEST AG : Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency
EQ
06/10Biotest AG Achieves Important Milestone in Phase III Study in Acquired Fibrinogen Deficiency
CI
06/09BIOTEST AG : Biotest AG opens 11th plasma collection centre in Czech Republic
EQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
06/22/2022 06/23/2022 06/24/2022 06/27/2022 06/28/2022 Date
41.5(c) 41.5(c) 42.6(c) 42.4(c) 42.1 Last
300 431 396 603 123 Volume
-0.72% 0.00% +2.65% -0.47% -0.71% Change
More quotes
Estimated financial data (e)
Sales 2022 550 M 584 M 584 M
Net income 2022 -34,1 M -36,2 M -36,2 M
Net Debt 2022 467 M 495 M 495 M
P/E ratio 2022 -40,2x
Yield 2022 0,09%
Sales 2023 583 M 619 M 619 M
Net income 2023 9,06 M 9,62 M 9,62 M
Net Debt 2023 513 M 544 M 544 M
P/E ratio 2023 153x
Yield 2023 0,13%
Capitalization 1 525 M 1 619 M 1 619 M
EV / Sales 2022 3,62x
EV / Sales 2023 3,50x
Nbr of Employees 1 967
Free-Float 55,1%
More Financials
Company
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood... 
Read more
Sector
Pharmaceuticals
Calendar
08/11Earnings Release
More about the company
Ratings of Biotest AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIOTEST AG
06/10BIOTEST AG : Biotest achieves important milestone in Phase III study in acquired fibrinoge..
EQ
06/10Biotest AG Achieves Important Milestone in Phase III Study in Acquired Fibrinogen Defic..
CI
06/09BIOTEST AG : Biotest AG opens 11th plasma collection centre in Czech Republic
EQ
06/09Biotest AG Opens 11th Plasma Collection Centre in Czech Republic
CI
05/24BIOTEST AG : Biotest AG opens 10th plasma collection centre in Czech Republic
EQ
05/24Biotest AG Opens 10th Plasma Collection Centre in Czech Republic
CI
05/06BIOTEST AG : Dr Bernhard Ehmer new Chairman of the Supervisory Board of Biotest AG
EQ
05/06BIOTEST AG : Ex-dividend day for final dividend
FA
05/05BIOTEST AG : Annual General Meeting approves dividend distribution
EQ
05/05Biotest Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 3..
CI
05/05BIOTEST AG : Biotest records sales of ? 115 million in the first quarter of 2022
EQ
05/02Biotest Names Successor For Outgoing COO
MT
05/02BIOTEST AG : Biotest Supervisory Board appoints new Management Board member
EQ
05/02Biotest AG Announces Board Changes
CI
04/25GRIFOLS, S.A. COMPLETED THE ACQUISIT : BIO3) from Tiancheng International Investment Limit..
CI
More news
News in other languages on BIOTEST AG
06/10BIOTEST AG : Biotest erreicht bedeutenden Meilenstein in Phase-III Studie bei erworbenem F..
06/10BIOTEST AG : Biotest erreicht bedeutenden Meilenstein in Phase-III Studie bei erworbenem F..
06/10Biotest AG franchit une étape importante dans l'étude de phase III sur la déficience ac..
06/09BIOTEST AG : Biotest AG eröffnet 11. Plasmasammelzentrum in Tschechien
06/09BIOTEST AG : Biotest AG eröffnet 11. Plasmasammelzentrum in Tschechien
More news
Chart BIOTEST AG
Duration : Period :
Biotest AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOTEST AG
Short TermMid-TermLong Term
TrendsBullishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 34,70 €
Average target price 36,58 €
Spread / Average Target 5,40%
EPS Revisions
Managers and Directors
Michael Ramroth Chairman-Management Board & CFO
Bernhard R. M. Ehmer Chairman-Supervisory Board
Jörg Schüttrumpf Chief Scientific Officer
Christian Polus Head-Information Technology
Georg Floß Chief Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOTEST AG-0.23%1 620
CSL LIMITED-6.70%90 814
SAMSUNG BIOLOGICS CO.,LTD.-10.74%45 825
WUXI BIOLOGICS (CAYMAN) INC.-16.59%41 498
BIOGEN INC.-11.67%31 038
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-12.56%24 084